Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis-Reference-Cited by-同舟云学术

Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis

Published:2023-12 Issue:12 Volume:18 Page:1756-1766
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Soo Ross A.,Cho Byoung Chul,Kim Joo-Hang,Ahn Myung-Ju,Lee Ki Hyeong,Zimina Anastasia,Orlov Sergey,Bondarenko Igor,Lee Yun-Gyoo,Lim Yueh Ni,Lee Sung Sook,Lee Kyung-Hee,Pang Yong Kek,Fong Chin Heng,Kang Jin Hyoung,Lim Chun Sen,Danchaivijitr Pongwut,Kilickap Saadettin,Yang James Chih-Hsin,Arslan Cagatay,Lee Hana,Park Seong Nam,Cicin Irfan

Funder

Yuhan

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference20 articles.

1. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers;Rangachari;Lung Cancer,2015

2. Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors;Taniguchi;Oncol Lett,2017

3. Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation;Arrieta;Radiat Oncol,2011

4. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non–small cell lung cancer with EGFR mutations;Heon;Clin Cancer Res,2012

5. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation;Park;Lung Cancer,2012

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape;Cancer Treatment Reviews;2024-11

2. The Role of Lazertinib in Patients With EGFR-Variant Non–Small Cell Lung Cancer;JAMA Oncology;2024-08-15

3. Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors;JAMA Oncology;2024-08-15

4. Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS);Cancer Communications;2024-07-17

5. First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials;Expert Review of Anticancer Therapy;2024-06-03